Amneal Pharmaceuticals Stock Up 57% Since June: Why the AI-Picked Pharma Stock Keeps Climbing
Amneal Pharmaceuticals (NASDAQ: AMRX) has become one of the stronger-performing U.S. pharmaceutical stocks in recent months, with shares up about 57.75% since an AI-driven InvestingPro selection on June 1, 2026. The rally has been supported by improving earnings, a series of product catalysts and the FDA approval of a key injectable drug in September.
The stock's performance is notable because the AI signal came before several of the catalysts that later supported the investment case. Amneal reported stronger-than-expected second-quarter results in July, while the U.S. Food and Drug Administration subsequently approved the company's lanreotide injection in September.
That does not mean an AI model predicted those individual events. Rather, the case illustrates how quantitative screening can identify companies with a combination of earnings momentum, valuation and business-growth characteristics before major catalysts become visible.
Why Amneal Pharmaceuticals Stock Has Rallied
The 57% gain in Amneal stock since June has not come from a single announcement.
The company has been building a diversified pharmaceutical portfolio spanning affordable medicines, specialty drugs and government-focused distribution through AvKARE. Its financial performance has also improved.
In the second quarter of 2026, Amneal generated $796.2 million in revenue, up about 10% year over year. GAAP net income reached $58 million, compared with $22 million a year earlier, while adjusted EBITDA rose to $206 million. Adjusted diluted EPS increased to $0.30, compared with $0.25 in the prior-year quarter.
The result gave investors evidence that the company's growth was being accompanied by improving profitability rather than relying entirely on future drug launches.
Amneal also raised its full-year 2026 guidance following the second-quarter results. Management now expects revenue of $3.1 billion to $3.2 billion, adjusted EBITDA of $750 million to $780 million and adjusted diluted EPS of $0.96 to $1.06.
FDA Approval Added Another Catalyst
A major development came in September when the FDA approved Amneal's lanreotide injection for the U.S. market.
The product is a generic version referencing Somatuline Depot and received Competitive Generic Therapy designation. Amneal said it launched the product immediately following approval.
The significance goes beyond simply adding another product to the portfolio.
Lanreotide is a complex injectable medicine, an area where manufacturing capabilities and regulatory expertise can create higher barriers to entry than in simpler generic drugs. Amneal has been expanding its injectable portfolio as part of its strategy to increase the contribution from more complex pharmaceutical products.
According to Investing.com, the reference drug targeted by Amneal's lanreotide product generated roughly $983 million in annual U.S. sales, giving investors an indication of the commercial opportunity.
Actual sales for Amneal will depend on pricing, market share, competition and the pace of commercialization, so the reference product's sales should not be interpreted as a forecast for Amneal's revenue.
The AI Signal Was Based on More Than Momentum
InvestingPro added Amneal to its Mid-Cap Movers strategy on June 1.
According to the platform, its quantitative models evaluated factors including historical financial data, valuation signals and forward-looking growth metrics. The models were using more than 15 years of financial data across more than 150 quantitative models.
At the time of the selection, InvestingPro reported a PEG ratio of 0.35 and a P/E ratio of 55.0 times. In its October review, the platform said the PEG ratio had fallen to approximately 0.01 as earnings growth outpaced the increase in the stock price.
For beginners, the PEG ratio compares a company's price-to-earnings valuation with its expected earnings growth. A lower PEG can indicate that a stock's valuation is more reasonable relative to its growth rate, although it should never be used on its own to decide whether a stock is attractive.
The important point is that the AI screen did not rely purely on the stock chart. Earnings growth and valuation were also part of the model's selection process.
Amneal's Earnings Momentum Is Strengthening
The company's second-quarter numbers provide a fundamental explanation for why investors have continued to pay attention to the stock.
Amneal's Affordable Medicines business generated $490 million in quarterly revenue, up 13% year over year. Its Specialty segment produced $149 million, up 17%, helped by products including CREXONT, BREKIYA and UNITHROID. AvKARE revenue declined 4% to $157 million because weaker low-margin distribution activity offset growth in the government channel.
The mix is important.
A pharmaceutical company with growth concentrated in a single product can face substantial volatility if competition arrives or a regulatory setback occurs. Amneal is attempting to spread its growth across complex generics, specialty products, injectables and biosimilars.
The company also reported that first-half revenue increased 7%, while adjusted EBITDA rose 16% and adjusted EPS increased 27% year over year.
That combination of revenue and profit growth has helped support the stock's rerating.
Kashiv Acquisition Adds a Longer-Term Growth Pillar
Another major part of the Amneal story is its planned acquisition of Kashiv BioSciences.
Amneal agreed in April to acquire Kashiv in a transaction involving $375 million in cash and 28.94 million Amneal Class A shares, plus potential contingent payments and royalties. The transaction is designed to establish a larger, integrated biosimilars platform.
Biosimilars are biologic medicines designed to be highly similar to already approved biological drugs. The opportunity is potentially significant because many major biologic medicines face patent expirations over the coming years.
Amneal has said the Kashiv combination could generate $400 million to $500 million in cumulative financial benefits through areas including tax benefits, local incentives and the elimination of certain milestone and profit-sharing obligations.
The acquisition therefore gives investors another potential source of growth beyond the company's existing generic and specialty-drug businesses.
But it also introduces execution risk. The transaction involves new shares, integration requirements and additional complexity, while the expected benefits depend on successful execution.
What Could Keep the Stock Climbing?
The near-term test is likely to be Amneal's next earnings report.
The company is expected to report third-quarter 2026 results around October 29, although the date remains subject to confirmation. Current estimates cited by market-data providers put quarterly EPS expectations around $0.23.
Investors will be looking for evidence that the strong first-half trajectory is continuing.
Key areas to watch include:
Revenue growth across Affordable Medicines and Specialty
Early contribution from newly launched products
Lanreotide sales and market share
Adjusted EBITDA margins
Free cash flow and debt reduction
Progress on the Kashiv acquisition
New FDA approvals and complex-generic launches
Management's full-year guidance
Amneal's pipeline also includes additional opportunities in areas such as injectables, biosimilars and specialty medicines. Its current pipeline lists products including omalizumab and denosumab biosimilars, although estimated approval and launch dates remain subject to regulatory outcomes.
The Biggest Risks After a 57% Rally
A strong run can change the risk-reward equation.
InvestingPro's October review noted that Amneal was trading at about 96.2% of its 52-week high, meaning much of the recent positive momentum was already reflected in the share price.
That makes upcoming earnings increasingly important.
There is also a valuation risk. A stock can continue to grow earnings while still becoming expensive if the share price rises faster than profits. Competition in generic medicines can put pressure on prices, while drug-development and regulatory timelines can change unexpectedly.
The Kashiv deal adds another layer. Although management expects substantial financial benefits, investors will ultimately judge the acquisition based on actual revenue contribution, margins, cash generation and progress toward deleveraging.
The company's debt position also deserves attention as it expands through acquisition.
What the AI Pick Really Tells Investors
Amneal's performance is an interesting example of how quantitative stock selection can work, but it should not be interpreted as proof that AI can consistently predict future winners.
The model identified Amneal before the lanreotide approval and before the latest earnings performance, but the stock's subsequent return resulted from actual business developments, not from the AI signal itself.
That distinction matters.
AI-driven investing tools can process large quantities of financial information and identify patterns that may be difficult to evaluate manually. But they cannot remove the uncertainty surrounding FDA decisions, drug pricing, competition, acquisitions or future earnings.
For investors, the better question is whether the underlying business continues to justify the stock's higher valuation.
Bottom Line
Amneal Pharmaceuticals has climbed about 57.75% since an AI-driven stock selection on June 1, 2026, with the rally later supported by stronger earnings, higher full-year guidance and the FDA approval of its lanreotide injection.
The company now has several potential growth engines, including complex generics, specialty medicines, injectables and the planned Kashiv biosimilars platform. Its second-quarter results showed solid revenue and profit momentum, while management raised its 2026 outlook.
The challenge is that the stock has already rerated sharply. Investors should therefore focus less on the fact that an AI model picked Amneal early and more on whether future earnings, new-product launches and the Kashiv transaction can support the higher expectations now embedded in the share price.
Follow the blog for more updates on AI-driven stock picks, pharmaceutical companies, FDA approvals and global markets.
This article is for informational and educational purposes only and should not be considered investment advice.